# Asklepios Fachkliniken München-Gauting

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/asklepios-fachkliniken-munchen-gauting/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 67 |
| Citations | 142,502 |
| City | Gauting |
| Country | DE |
| Description | Asklepios Fachkliniken München-Gauting is a research organisation in Gauting, DE. OpenAlex records 2,060 works and 142,502 citations for it. 486 researchers list it as their most recent affiliation. |
| Homepage | https://www.asklepios.com/gauting/ |
| OpenAlex ID | https://openalex.org/I4210125421 |
| Researchers | 486 |
| ROR ID | https://ror.org/02v4fpg03 |
| Type | healthcare |
| Works | 2,060 |

## University papers

- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-comparing-cisplatin-plus-gemcitabine-with-cisplatin-plus/)
- [Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy](https://scholariq.org/papers/randomized-phase-iii-trial-of-pemetrexed-versus-docetaxel-in-patients-with-non/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial](https://scholariq.org/papers/cetuximab-plus-chemotherapy-in-patients-with-advanced-non-small-cell-lung-cancer/)
- [Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial](https://scholariq.org/papers/docetaxel-plus-nintedanib-versus-docetaxel-plus-placebo-in-patients-with/)
- [Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations](https://scholariq.org/papers/tepotinib-in-non-small-cell-lung-cancer-with-i-met-i-exon-14-skipping-mutations/)
- [Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)](https://scholariq.org/papers/updated-overall-survival-and-pd-l1-subgroup-analysis-of-patients-with-extensive/)
- [Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-trial-of-ipilimumab-combined-with-paclitaxel-and-carboplatin-in/)
- [Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/randomized-phase-iii-placebo-controlled-trial-of-carboplatin-and-paclitaxel-with/)
- [Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-versus-docetaxel-for-previously-treated-advanced-or/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Chronic Obstructive Pulmonary Disease (COPD) Research](https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Respiratory Support and Mechanisms](https://scholariq.org/topics/respiratory-support-and-mechanisms/)
- [Pleural and Pulmonary Diseases](https://scholariq.org/topics/pleural-and-pulmonary-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.